Johnson & Johnson in talks to run a vaccine booster trial in South Africa

accreditation
0:00
play article
Subscribers can listen to this article
SA is currently exiting its third wave of infections with another resurgence expected later this year.
SA is currently exiting its third wave of infections with another resurgence expected later this year.
Getty Images

Talks are under way with Johnson & Johnson about running a booster trial in South Africa after the company’s Covid-19 vaccine was used in a mass trial of almost half a million health workers in the country.

The trial will include participants from that study, known as Sisonke, and could possibly start in October, according to Glenda Gray, who is co-lead of the mass trial. It will add to a booster study in the country using ImmunityBio’s shot that has already started. 

South Africa, where scientists believe that about a quarter of a million people have died of Covid-19, has hosted vaccine trials for companies including Novavax, Pfizer, AstraZeneca and J&J. The country is currently exiting its third wave of infections with another resurgence expected later this year.

"We are talking to J&J and the department of health about the feasibility of a boost," said Gray, who is also the president of the South African Medical Research Council. "We would like to start that in October, in time for the fourth wave."

A number of the world’s richest countries have started giving some of their citizens additional shots with the aim of bolstering the immune response against the virus several months after their initial inoculation, as the number of antibodies may wane.

While ImmunityBio’s trial is in its first phase, with about 50 participants, it is expected to reach its third and final stage in October, with about 10 000 people receiving doses, she said.


We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Rand - Dollar
16.14
-1.3%
Rand - Pound
21.36
-0.0%
Rand - Euro
18.26
-0.0%
Rand - Aus dollar
11.30
-0.0%
Rand - Yen
0.14
-0.0%
Gold
1,783.48
0.0%
Silver
22.55
0.0%
Palladium
1,816.00
0.0%
Platinum
936.31
0.0%
Brent Crude
69.88
+0.3%
Top 40
64,307
-0.4%
All Share
70,808
-0.3%
Resource 10
66,503
-1.6%
Industrial 25
93,791
+0.1%
Financial 15
13,982
+0.7%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot